Leading the Way in Life Science Technologies

GEN Exclusives

More »

April 15, Vol. 31, No. 8

  • Feature Articles

    • Oligonucleotide Production Gearing Up
    • Vicki Glaser
    • Oligonucleotide-based drugs continue to flow into developmental pipelines, and the relatively large numbers now being tested in humans and progressing through late-stage clinical studies have buoyed optimism that commercialization of oligo therapeutics may finally come sooner rather than later In ... more »
    • GEN's 30th Anniversary: Gene Patenting
    • Without Drs Herbert Boyer and Stan Cohen, the biotechnology industry would probably not exist, or at least appear in the form that we currently know it And, of course, there would be no GEN However, these two scientific pioneers developed ... more »
    • Refining GPCR Discovery Approaches
    • Ellyn Kerr
    • GPCRs constitute the largest class of known targets in commercial drug discovery today—collectively the targets of at least 30% of currently marketed drugs Yet, as heptahelical transmembrane proteins involved in divergent and manifold signaling pathways, they can confound conventional drug ... more »
    • Managing PTMs in Protein Therapeutics
    • K. John Morrow, Jr.
    • As more and more biopharmaceuticals move along the torturous process of development, clinical evaluation, and approval, dealing with changes to these complex protein molecules becomes increasingly paramount A number of meetings and symposia have examined this question lately, and it’s ... more »
    • Flow Cytometry Stakes Out New Territory
    • Gail Dutton
    • Flow cytometers are becoming the instrument of choice in a growing number of applications, including marine biology, cancer biology, drug screening, cell-cycle analysis, intracellular analysis, rare event detection, immunophenotyping, and stem cell research Increasingly firms are developing benchtop systems that ... more »